NASDAQ:IRON • US2546041011
The current stock price of IRON is 63.75 USD. Today IRON is down by -0.75%. In the past month the price decreased by -19.43%. In the past year, price increased by 25.89%.
ChartMill assigns a technical rating of 0 / 10 to IRON. When comparing the yearly performance of all stocks, IRON is a bad performer in the overall market: 69.07% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to IRON. IRON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
19 analysts have analysed IRON and the average price target is 104.64 USD. This implies a price increase of 64.13% is expected in the next year compared to the current price of 63.75.
Over the last trailing twelve months IRON reported a non-GAAP Earnings per Share(EPS) of -6.01. The EPS decreased by -50.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.3% | ||
| ROE | -28.68% | ||
| Debt/Equity | 0.04 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.31 | 402.17B | ||
| AMGN | AMGEN INC | 16.54 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.83 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.96 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.65 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.32 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.79 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.24 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 341.02 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
IPO: 2020-08-12
DISC MEDICINE INC
321 Arsenal Street, Suite 101
Watertown MASSACHUSETTS US
Employees: 155
Phone: 16176749274
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
The current stock price of IRON is 63.75 USD. The price decreased by -0.75% in the last trading session.
IRON does not pay a dividend.
IRON has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
19 analysts have analysed IRON and the average price target is 104.64 USD. This implies a price increase of 64.13% is expected in the next year compared to the current price of 63.75.
DISC MEDICINE INC (IRON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.01).
DISC MEDICINE INC (IRON) has a market capitalization of 2.43B USD. This makes IRON a Mid Cap stock.